Last year, Immuno-oncology (I/O) drove nearly 30% of licensing activity in Oncology while half of the 20 largest Oncology licensing deals were in I/O. Areas for investment include immune checkpoint antibodies, cell therapies, and other biologics, but how successful are I/O investment strategies? Genetically validated targets are well known to be twice as likely to succeed in the clinic, but are investors considering the biology when making decisions? Dr. Hardison will review recent deals activity in Immuno-oncology, identify trends and drivers of that activity, examine the role underlying biology plays in clinical success, and look at how to apply that knowledge to future investments.
Session ID: 551541